iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note issued to investors on Friday,Benzinga reports. They currently have a $46.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Tuesday, November 12th. Finally, Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $8.23 on Friday. iTeos Therapeutics has a 52 week low of $7.99 and a 52 week high of $18.75. The stock has a 50 day moving average price of $10.27 and a two-hundred day moving average price of $14.01. The stock has a market capitalization of $300.64 million, a PE ratio of -2.61 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.13. Research analysts forecast that iTeos Therapeutics will post -3.57 EPS for the current year.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. The Manufacturers Life Insurance Company boosted its stake in shares of iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the last quarter. Creative Planning boosted its position in iTeos Therapeutics by 6.5% in the third quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after purchasing an additional 1,196 shares during the last quarter. nVerses Capital LLC increased its position in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of iTeos Therapeutics by 4.9% during the 1st quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after purchasing an additional 1,817 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares during the period. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.